Gilead doles out $280M up­front to re­gain Trodelvy rights in Chi­na, oth­er re­gion­al ter­ri­to­ries

A lit­tle over two months af­ter Trodelvy earned its first ap­proval in Chi­na, Gilead is mak­ing moves to re­gain the drug’s rights in the coun­try and the sur­round­ing re­gion.

The big bio­phar­ma will pay Ever­est Med­i­cines $280 mil­lion up­front for Trodelvy’s Chi­na rights and promise an­oth­er $175 mil­lion in mile­stone pay­ments. Tues­day’s move comes af­ter Ever­est nabbed its first Chi­na ap­proval for Trodelvy in June, for ad­vanced forms of triple neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER